Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Diagnosis of AA with at least 2 patches of alopecia involving the scalp, AT or AU

• Stable hair loss present for 6 months or longer

• No treatment for alopecia areata in the past 1 month

• No evidence of spontaneous hair regrowth

Exclusion Criteria:

• Patients have received treatment known to affect alopecia areata within 1 month of enrolling in the study

• Patients whose current episode of AT or AU is more than 5 years

• Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)

• Patients known to be HIV or hepatitis B or C positive

• Patients with positive tuberculin skin test or positive QuantiFERON® TB test

• Patients with leukopenia or anemia

• Patients with renal or hepatic impairment

• Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNF-α inhibitors

• Women who are pregnant or nursing